KDM1A and familial dilated cardiomyopathy: The inhibition of mTOR, MAPK, and LSD1 significantly rescues the LMNA-related DCM phenotype in mice [75,138,175], and a novel and selective p38 MAPK inhibitor is now in a phase 3 clinical trial in LMNA-related DCM [176].